trending Market Intelligence /marketintelligence/en/news-insights/trending/dfLOmLLeisopDkZ93PHf1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Merck & Co.'s Keytruda combo shows mixed results in lung cancer study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Merck & Co.'s Keytruda combo shows mixed results in lung cancer study

Merck & Co. Inc. said a combination of its blockbuster drug Keytruda and chemotherapy significantly improved the time certain lung cancer patients lived without their disease worsening compared to chemotherapy alone.

However, Keytruda failed to significantly improve the time patients lived since the start of treatment, also called overall survival, compared to just chemotherapy.

Results of the late-stage study showed the drug arm met one primary goal of the study by showing improvement in patient's survival duration without progression of cancer.

The Kenilworth, N.J.-based pharmaceutical giant was evaluating the Keytruda-chemotherapy combination as an initial treatment for patients with extensive-stage small cell lung cancer during the phase 3 trial called Keynote-604.

Small cell lung cancer is a fast-growing disease that spreads very quickly and can create large tumors. The disease is categorized as an extensive stage when cancer spreads widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest or to other parts of the body.

Merck will discuss the results of the trial with regulatory bodies and will present them at an upcoming medical meeting.